Docetaxel for the post-surgery treatment of patients with node-positive breast cancer

Review

(2218) Views  (332) Full article downloads

Authors: Shubham Pant, Meena P Chilukuri, Bhuvaneswari Ramaswamy

Published Date April 2008 Volume 2008:4(2) Pages 419 - 424

DOI: http://dx.doi.org/10.2147/TCRM.S1766

Shubham Pant¹, Meena P Chilukuri², Bhuvaneswari Ramaswamy¹

¹Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University, Columbus, Ohio, USA; ²Mount Carmel Medical center, Columbus, Ohio

Abstract: Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorporated into various adjuvant trials and have demonstrated a significant benefit in the management of early stage breast cancer. Clinical trials using combinations of taxanes with targeted therapy have also shown considerable activity in breast cancer. This article reviews the pharmacology of docetaxel, a semi-synthetic taxane, and the clinical trials supporting its use in patients with node-positive breast cancer.

Keywords: docetaxel, node-positive breast cancer, post-surgery treatment, taxanes

Other articles by Dr Bhuvaneswari Ramaswamy